Biosimilars: still a work in progress

Evidence is pointing to most pharmacists still struggling to come to grips with their role in providing biosimilar medicines It’s now been seven years since the Pharmaceutical Benefits Advisory Committee (PBAC) made the decision to consider the marking as equivalent—or “a” flagging—of biosimilar medicines and their reference products, allowing pharmacists to substitute biosimilars for originator

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Going ‘above and beyond’ for the pharmacy profession
Next The week in review